



Press Release

CRITICAL OUTCOME TECHNOLOGIES INC. PRESENTING AT THE 2013 BIO INTERNATIONAL CONVENTION

Dr. Danter to Participate in Round Table Discussion with Gates Foundation

London, Ontario (April 19, 2013): Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSXV: COT) announced today that Dr. Wayne Danter, President & CEO, will be presenting at the 2013 BIO International Convention in Chicago on Tuesday, April 23 at 2:30 p.m. CDT.

Dr. Danter’s presentation entitled “CHEMSAS®: COTI’s Proprietary Artificial Intelligence Platform for Drug Discovery and So Much More” will highlight the versatility of COTI’s validated proprietary discovery platform. Dr. Danter will also be meeting with potential licensing partners for the Company’s COTI-2 oncology program (the most advanced program developed from COTI’s CHEMSAS® platform) and with parties interested in accelerating their drug discovery projects.

On Wednesday, April 24, Dr. Danter will be participating in a round table discussion with the Bill and Melinda Gates Foundation’s Global Health Program. The round table discussion will focus on ways that the industry and the Gates Foundation can collaborate to provide health solutions to meet challenges facing developing countries.

About Critical Outcome Technologies Inc.

COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI’S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com

Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416-500-8061
Email: trevor@heislercommunications.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.